Marangi Michele, Pistritto Giuseppa
Department of Economic Strategy of Pharmaceutical Products, Italian Medicines Agency, Rome, Italy.
Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Front Pharmacol. 2018 Apr 20;9:396. doi: 10.3389/fphar.2018.00396. eCollection 2018.
One of the most revolutionary technologies in recent years in the field of molecular biology is CRISPR-Cas9. CRISPR technology is a promising tool for gene editing that provides researchers the opportunity to easily alter DNA sequences and modify gene function. Its many potential applications include correcting genetic defects, treating and preventing the spread of diseases. Cystic fibrosis (CF) is one of the most common lethal genetic diseases caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. Although CF is an old acquaintance, there is still no effective/resolutive cure. Life expectancy has improved thanks to the combination of various treatments, but it is generally below average. Recently, a significant number of additional key medications have become licensed in Europe for the CF treatment including CFTR modulators. But innovative genomically-guided therapies have begun for CF and it is predictable that this will lead to rapid improvements in CF clinical disease and survival in the next decades. In this way, CRISPR-Cas9 approach may represent a valid tool to repair the CFTR mutation and hopeful results were obtained in tissue and animal models of CF disease.
近年来分子生物学领域最具革命性的技术之一是CRISPR-Cas9。CRISPR技术是一种很有前景的基因编辑工具,为研究人员提供了轻松改变DNA序列和修改基因功能的机会。其众多潜在应用包括纠正基因缺陷、治疗和预防疾病传播。囊性纤维化(CF)是由CF跨膜传导调节因子(CFTR)基因突变引起的最常见致命遗传病之一。尽管CF是个老相识,但仍然没有有效的治愈方法。由于多种治疗方法的结合,预期寿命有所提高,但总体仍低于平均水平。最近,欧洲有大量额外的关键药物获批用于CF治疗,包括CFTR调节剂。但针对CF的创新性基因组指导疗法已经开始,预计这将在未来几十年迅速改善CF临床疾病和生存率。通过这种方式,CRISPR-Cas9方法可能是修复CFTR突变的有效工具,并且在CF疾病的组织和动物模型中取得了令人期待的结果。